Pharming « Terug naar discussie overzicht

donderdag 28-10-10

233 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 11 12 » | Laatste

Omlaag ↓

[verwijderd] 28 oktober 2010 16:25

daar was ook de 0.234 en waar denk je aan nu je niks hoort van Pharming? goed of slecht voorgevoel

[verwijderd] 28 oktober 2010 16:26

quote:
Tyon schreef:
Hallo.

Ik ben beginnend belegger bij Binckbank.
Ik zie dat U het steeds hebt over het boek.
Wat kan ik zien aan Bied,Biedvol,laat,laatvol.
Ik geloof dat te maken heeft met wat er te wachten staat.

Maar wat hier nu het fijne van is ,??
Kan iemand mij dit uitleggen.

Gr

Moet je eerst als "Trader of Daytrader"vermeld staan.
Trader : moet je minimaal 3 aan-of verkopen gedaan hebben.
Daytrader nog meer...

groet,,,

[verwijderd] 28 oktober 2010 16:27

quote:
BBQ schreef:
[...]
Ik heb een auto gekocht, maar het is een schakel auto maar ik weet niet hoe ik moet schakelen...
Ik heb sinds mei mijn rijbewijs...
Ik zou zeggen: lees je theorie nog eens door...

ga eens lekker in de tuin zitten!

[verwijderd] 28 oktober 2010 16:30

op 0.23 staat weer een miljoen

[verwijderd] 28 oktober 2010 16:31

quote:
silfer schreef:
Ik voel iets aankomen.....
Heb nog geen reactie per mail ontvangen, is mij te stil........

dus er komt een pb aan aangaande de opties of er is iets neagtiefs aangaande de epar....

[verwijderd] 28 oktober 2010 16:31

toch weer iemand die er 200 stuks bestens kocht.... BBQ zeker

[verwijderd] 28 oktober 2010 16:32

Bedankt BBQ geweldig

[verwijderd] 28 oktober 2010 16:32

0.233

[verwijderd] 28 oktober 2010 16:32

quote:
't zal maar gebeuren schreef:
exact hetzelfde liedje als gisteren! slot 0,23/0,231

ik heb het voorspeld, ONKRUID.

[verwijderd] 28 oktober 2010 16:33

en daar is het goede nieuws

[verwijderd] 28 oktober 2010 16:33

Daar gaat ie

[verwijderd] 28 oktober 2010 16:34

koper!!!

[verwijderd] 28 oktober 2010 16:35

als een rakettttttt voorkennis en nog geen pb!!!!!! freeze komt eraan

feli met je 200 stukkies BBQ

[verwijderd] 28 oktober 2010 16:36

spuiten maar !

[verwijderd] 28 oktober 2010 16:36

je kan ze zometeen niet meer krijgen....

[verwijderd] 28 oktober 2010 16:36

0.257

[verwijderd] 28 oktober 2010 16:37

en nu lekker afwachten.

[verwijderd] 28 oktober 2010 16:37

zonder pb 4 mlj omzet erbij

wesmail 28 oktober 2010 16:37

eiden, The Netherlands, and Stockholm, Sweden October 28, 2010. Biotech company Pharming Group NV (Pharming or “the Company”) (NYSE Euronext: PHARM) and Swedish Orphan Biovitrum (Sobi) (STO: SOBI) today announced that the European Commission has granted Pharming Marketing Authorization for its lead product Ruconest™ for the treatment of acute attacks of Hereditary Angioedema (HAE). Pharming will now receive a €5 million milestone payment from marketing and distribution partner Sobi.

Following the unanimous positive opinion adopted by the Committee for Medicinal Products for Human Use (CHMP), Ruconest’s Marketing Authorization has now been ratified by the European Committee.

Patients suffering from HAE experience unpredictable, painful and debilitating attacks, due to reduced levels of C1 inhibitor, resulting in intense swelling of parts of the body (for example, face, throat, abdomen) which can last up to five days if left untreated. Ruconest is a recombinant version of the human C1 inhibitor protein, produced by Pharming’s proprietary transgenic technology. As published in last October’s issue of the Journal of Allergy and Clinical Immunology, Ruconest has been shown to have excellent efficacy and safety. Pharming has withdrawn the orphan status application in order to avoid delays in commercializing the product.

Dr Marco Cicardi, MD, Professor of Internal Medicine at the University of Milan, Italy, said: “Patients with HAE experience an average of eight attacks a year. This distressing and potentially life-threatening condition requires new approaches for acute treatment and Ruconest offers this. This recombinant product is the only HAE treatment achieving circa 90% of success in treating attacks.”

Ruconest is now approved for use in the 27 EU countries plus Norway, Iceland and Liechtenstein. Sobi will launch Ruconest initially in Germany, the UK, Sweden, Finland and Denmark, followed by a rolling launch in each of the other European Area countries.

Sijmen de Vries, CEO of Pharming: "The granting of marketing authorization for Ruconest™ is a very important step in Pharming’s evolution from a drug development company to a commercial specialty pharmaceutical business. Together with our marketing partners, we look forward to the launch of Ruconest this year and making this novel new treatment available to the European HAE population. I would also like to thank the many European physicians and patients who participated in our clinical trial program with Ruconest.”

“Ruconest has the potential to offer patients with significant medical needs a safe and valuable alternative treatment. Moreover, it is a good fit with Sobi’s commercial portfolio of rare disease products. We are very much looking forward to exciting fruitful partnership with Pharming and the opportunity to provide this new exciting product to patients who need it in Europe,” said Martin Nicklasson, CEO of Sobi.

Conference call information
Pharming’s management team will be available for questions on today’s marketing approval of Ruconest in a conference call tomorrow, October 29, at 8:30 am CET. To participate in the call, please call one of the following numbers:
- From the Netherlands: 0800 265 8543 (toll-free) or +31 (0)45 631 6901
- From the UK: 0800 358 0886 (toll-free) or +44 207 153 2027

An audio cast of the conference calls will be available on Pharming's website shortly thereafter.

About Ruconest (Rhucin in non-European countries)
Ruconest (INN conestat alfa) is a recombinant version of the human C1 inhibitor (C1INH) protein. The product is produced through Pharming’s proprietary technology in milk of transgenic rabbits. Ruconest has identical amino acid sequence as endogenous human C1INH. The safety and efficacy of Ruconest has been demonstrated in two placebo controlled and four open-label studies. Both randomized placebo-controlled clinical trials showed statistically significant and clinically relevant improvement in time to relief of symptoms and time to minimal symptoms compared to placebo.
The European public assessment report (EPAR) for Ruconest will be published on the EMA website. It explains how the CHMP assessed Ruconest and its recommendations on the conditions for use of Ruconest.

About Hereditary Angioedema
HAE is a human genetic disorder in which the patient is deficient in or lacks a functional plasma protein C1 inhibitor, resulting in an overreaction of the immune system. The disease is characterized by unpredictable and debilitating episodes of intense swelling of the extremities, face, trunk, genitals, abdomen and upper airway, which may last up to five days when untreated. In addition to the life-threatening nature of the disease in case of laryngeal attacks, quality of life for individuals with the disease may be seriously impaired. Approximately one in 30,000 individuals (1:10,000 – 1:50,000) suffers from HAE with an average of approximately eight acute attacks per year.

About Swedish Orphan Biovitrum
Swedish Orphan Biovitrum is a Swedish based niche specialty pharmaceutical company with an international market presence. The company is focused on providing and developing specialist pharmaceuticals for rare disease patients with high medical needs. The portfolio consists of about 60 marketed products and an emerging late stage clinical development pipe-line. Our focus areas are: hemophilia, inflammation/autoimmune diseases, fat malabsorption, cancer and inherited metabolic disorders. Swedish Orphan Biovitrum had pro-forma revenues 2009e of about 2 BSEK and approximately 500 employees. The head office is located in Sweden and the share (STO: SOBI) is listed on NASDAQ OMX Stockholm. For more information please visit www.sobi.com.

About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of genetic disorders, specialty products for surgical indications, and nutritional products. Pharming’s lead product Ruconest™ (Rhucin in non-EU territories) has Market Authorization in the European Economic Area. The product is also under development for follow-on indications, i.e. antibody-mediated rejection (AMR) and delayed graft function (DGF) following kidney transplantation. The technologies of the Company include innovative platforms for the production of protein therapeutics, including technology and processes for the purification and formulation of these products. Additional information is available on the Pharming website www.pharming.com.

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.

Swedish Orphan Biovitrum may be required to disclose the information provided herein pursuant to the Swedish Securities Markets Act. The information was provided for public release on October 28, 2010 at 16:30 a.m. CET.

For more information please contact:
Pharming Group NV
Marjolein van Helmond, T: +31 (0)71 52 47 431 or +31 (0)6 109 299 54 or E: m.helmond@pharming.com

Swedish Orphan Biovitrum
Erik Kinnman, VP Investor Relations, T: +46 73 422 15 40 or E: erik.kinnman@sobi.com
Martin Nicklasson, CEO, T: +46 8 697 20 00

Financial Dynamics
Julia Phillips, T: +44 20 7269 7187
John Dineen, T: +44 20 7269 7193

[verwijderd] 28 oktober 2010 16:38

10mlj omzet , geen pb.......

233 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 11 12 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd	26 apr 2024 17:35
Koers	0,900
Verschil	+0,019 (+2,16%)
Hoog	0,903
Laag	0,883
Volume	3.641.122
Volume gemiddeld	6.805.258
Volume gisteren	4.203.859

Pharming nieuws

19 apr	Pharming lost voor 123 miljoen euro a...
18 apr	Pharming rondt plaatsing obligaties af
18 apr	Pharming vervangt converteerbare lening
08 apr	Pharming rondt rekrutering voor klini...
14 mrt	CEO: Pharming haalt omzet uit steeds ...
14 mrt	Lichte plus voor AEX voorzien; zullen...
14 mrt	Pharming rekent ook voor 2024 op dubb...
13 mrt	Slotcall: Twijfel slaat toe bij chipp...
11 mrt	Beursblik: hogere jaaromzet Pharming ...
11 mrt	AEX gaat opnieuw rode opening tegemoe...	1

Meer ››